Metachronous gastric cancer prevention with aspirin:A multi-center randomized trial

Not Applicable

• Conditions: Patients who underwent endoscopic submucosal dissection (ESD) for early gastric cancer

• Registration Number: JPRN-UMIN000031302
• Lead Sponsor: MEGA trial Group

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2018-02-14
• Last Update Posted: 17 October 2023
• Study Completion: 2027-05-31

Recruitment & Eligibility

• Status: Complete: follow-up complete
• Sex: All
• Target Recruitment: 50

Inclusion Criteria

Not provided

Exclusion Criteria

1) Allergy to aspirin treatment 2) Other gastric neoplasm including low grade adenoma remain 3) A history of H. pylori eradication therapy received more than 5 years ago 4) Lesions of Siewert Type II (<2 cm from the OGJ at the epicenter) 5) A history of gastric surgery 6) Severe co-morbidities and estimated life expectancy less than 3 years 7) Already on aspirin or other antithrombotic drugs prior to randomization 8) Using NSAIDs 9) Using Metformin 10) A history of peptic ulcers 11) A history of stroke 12) Receiving chemotherapy 13) Disorder of blood coagulation or platelet < 100,000/microliter 14) Pregnancy 15) Breast-feeding 16) Lack of informed consent

Study & Design

• Study Type: Interventional
• Study Design: Not specified